THROMBOGENICS'S TB-403 HAS POTENTIAL IN PEDIATRIC BRAIN CANCER

     (The following press release from ThromboGenics NV was received by e-mail. 
The sender verified the statement.) 
New Paper in Cell highlights the potential role of TB-403 (anti-PlGF) in the 
treatment of medulloblastoma, a pediatric brain tumor 
Leuven, 28 February 2013 – ThromboGenics NV (Euronext Brussels: THR), and 
co-development partner BioInvent International AB (OMXS: BINV), announce today 
the publication of a paper in the prestigious journal Cell, highlighting the 
potential of TB-403 to improve the treatment of medulloblastoma, the most 
common brain tumor in children. 
The Cell publication highlights for the first time a new mechanism of action 
showing that PlGF plays a vital role in the brain and that its expression is 
required for the growth and spread of medulloblastoma.      
The novel positive findings in this paper provide evidence that could warrant 
further development of TB-403 as one of the first targeted therapies to treat 
this childhood cancer. TB-403 is a monoclonal antibody against placental growth 
factor (PlGF). PIGF is a naturally occurring protein that belongs to the family 
of vascular endothelial growth factors (VEGF) that promote the formation of 
blood vessels. 
TB-403 was in-licensed by ThromboGenics from the Flanders Institute for 
Biotechnology (VIB), where the therapeutic potential of anti-PlGF agents to 
treat cancer was first developed by Prof. Peter Carmeliet at the University of 
Leuven, Belgium.
This Cell paper is reporting the findings of new pre-clinical research 
performed at the Massachusetts General Hospital in Harvard (Boston), in 
collaboration with the team of Prof Peter Carmeliet. 
With an emerging ophthalmologic franchise, Thrombogenics is also evaluating the 
role of TB-403 for ophthalmic indications. 
About ThromboGenics
ThromboGenics is an integrated biopharmaceutical company focused on developing 
and commercializing innovative ophthalmic medicines. The Company’s lead 
product, JETREA® (ocriplasmin), has been approved by the US FDA for the 
treatment of symptomatic VMA and was launched in January 2013.   
In March 2012, ThromboGenics signed a strategic partnership with Alcon 
(Novartis) for the commercialization of JETREA® outside the United States. 
Under this agreement, ThromboGenics could receive up to a total of €375 million 
in up-front and milestone payments. It will receive significant royalties from 
Alcon’s net sales of JETREA®. ThromboGenics and Alcon intend to share the costs 
equally of developing JETREA® for a number of new vitreoretinal indications.  
The JETREA European Marketing Authorisation Application is currently under 
review by the European Medicines Agency. Following the positive CHMP 
recommendation, a final decision by the European Commission on European 
approval is expected in the first half of 2013. 
ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor), 
formerly referred to as TB-403, for the treatment of ophthalmic indications. 
ThromboGenics is headquartered in Leuven, Belgium, and has-offices in Iselin, 
NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext 
Brussels exchange under the symbol THR. More information is available at 
www.thrombogenics.com.  
About BioInvent                                                                  
BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a 
research-based pharmaceutical company focused on discovery and development of 
innovative antibody-based drugs against cancer. The Company's pipeline 
currently includes three product candidates for the treatment of cancer.  
The company's competitive position is underpinned by n-CoDeR®, a proprietary 
antibody development platform. The scope and strength of this platform is also 
used to develop antibody-based drugs in collaboration with partners who finance 
the development of the new drug, and provide BioInvent the right to milestone 
payments and royalties on sales. These partners include Bayer HealthCare, 
Daiichi Sankyo, Mitsubishi Tanabe and Servier.  More information is available 
at www.bioinvent.com.  
Important information about forward-looking statements 
Certain statements in this press release may be considered “forward-looking”. 
Such forward-looking statements are based on current expectations, and, 
accordingly, entail and are influenced by various risks and uncertainties. The 
Company therefore cannot provide any assurance that such forward-looking 
statements will materialize and does not assume an obligation to update or 
revise any forward-looking statement, whether as a result of new information, 
future events or any other reason. Additional information concerning risks and 
uncertainties affecting the business and other factors that could cause actual 
results to differ materially from any forward-looking statement is contained in 
the Company’s Annual Report.
This press release does not constitute an offer or invitation for the sale or 
purchase of securities or assets of ThromboGenics in any jurisdiction.  No 
securities of ThromboGenics may be offered or sold within the United States 
without registration under the U.S. Securities Act of 1933, as amended, or in 
compliance with an exemption therefrom, and in accordance with any applicable 
U.S. state securities laws. 
 
Press spacebar to pause and continue. Press esc to stop.